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ABSTRACT 
Some  traditional  Chinese  medical  (TCM)  formulations  shown  to  have  anti-tumor  actions  in  patients  with  various  solid tumours.  However,  the 
mechanisms of the potential anticancer action are rarely reported. In the present study, we found that extracts from pharmaceutical raw materials 
consisting of ROR (Red ginseng, Ophiopogon japonicus, Radix Astragali) could significantly improve the proliferation rate and cytotoxic activity of 
cytokine-induced killer (CIK) cells, which is a heterogeneous population of polyclonal T lymphocytes sharing NK (Natural Killer) phenotype and 
functional  properties.  The  extracts  were  prepared  using  modified  ethanol-water  reflux  method.  Pharmacodynamic  test  results  showed  that  5% 
ROR-adding CIK Cells group performs 2.8 folds proliferation  multiples than that of no ROR-adding CIK cells group,  meanwhile the cytotoxic 
activity to K562 tumor cell has also a significant difference between them. In conclusion, ROR-adding CIK cells group exhibits stronger proliferation 
and  cytotoxicity  than  no  ROR-adding  CIK  cells  group,  and  the  results  provided  a  new  experimental  evidence  for  TCM’s  application  in 
CIK-immunotherapy. 
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INTRODUCTION 
Immunotherapy  stimulating  the  immune  system  and 
enhancing  the  patient’s  own  anti-tumor  ability  is  an 
alternative  and  promising  way  to  treat  cancer. 
Cytokine-induced killer (CIK) cells are a heterogeneous 
population  of  polyclonal  T  lymphocytes  sharing  NK 
(Natural  Killer)  phenotype  and  functional  properties. 
Initially described by Schmidt-Wolf et al. in 1991
1, CIK 
cells  are  endowed  with  a  potent  MHC-unrestricted 
anti-tumor  activity  and  can  be  efficiently  expanded 
in vitro  from  bone  marrow  or  peripheral  blood 
mononuclear (PBMC) by the timed addition of IFN-γ, Ab 
anti-CD3 and IL-2
2-4. The first property is the possibility 
of CIK cells to be ex vivo expanded to adequate numbers 
for effective and multiple in vivo infusions. CIK cells are 
therefore, suitable for the immunotherapy against tumor 
cells, especially residual tumor cells. 
Traditional  Asian  Medicine  has  been  documented  for 
centuries in China, Korea, Japan, and other countries in 
Asia
5. The traditional practice has been used extensively 
in  therapy  and  prevention  of  various  disorders  and 
diseases,  including  cancer.  Recent  studies  of  traditional 
Chinese Medicine (TCM) in cancer have been focused on 
molecules extracted and purified from herbs. Furthermore, 
Some  traditional  Chinese  medical  formulation,  main 
ingredients  including  phytohemagglutinin,  isoﬂavonoid, Chen Chun
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saponins and polysaccharide etc., used as an adjuvant in 
cancer  treatment  or  as  a  phytochemical  immune 
modulator  to  strengthen  the  host  defense  system,  have 
shown extensively to have anticancer actions in patients 
with various tumours
6-11. In the last decades, the effects of 
redginseng  extracts,  the  active  components  of  Panax 
ginseng,  were  evaluated  on  transplantable  tumors, 
proliferation of lymphocyte, two-stage model and rat liver 
lipid  peroxidation
10.  Various  bioactive  components 
extracted from Ophiopogon japonicus (Thunb.) KerGawl 
tuber,  such  as  homoisoflavonoid,  saponins  and 
polysaccharide,  was  also  evaluated
11.  Radix  astragali 
(Huang qi), dried root of Astragalus membranaceus Bge. 
Var.  mongholicus,  was  considered  as  a  tonic  in  the 
traditional  Chinese  medicine.  Many  researchers  found 
that  R.  astragali  could  activate  the  cytotoxicity  of 
lymphocytes to increase the secretion of IL-2 and IFN-γ
12. 
The  sound  reason  seems  to  be  caused  by  containing 
several  bioactive  constituents  such  as  isoﬂavonoids, 
saponins, and polysaccharides
13-14 
Thus, in present study three immune function-enhancing 
agents’  formulation  consisting  of  Redginseng  O. 
japonicus,  R.  Astragali  (abbreviated  as  ROR),  were 
investigated  for  the  effect  on  proliferation  and 
cytotoxicity  of  CIK  cells  using  a  modified  extraction 
method.  The  aim  was  to  determine  the  feasibility  of 
generating a sufficient number of CIK cells to assess the 
toxicity of this regimen, and to evaluate its ability to exert 
anti-tumor effect. 
 
MATERIALS AND METHODS 
ROR extraction and solution preparation 
The ROR extracts  preparation  was  a  slight  modification 
of the method described by previous study
15. 300 grams 
of  dry  and  minced  ROR  (100  grams  each  agent)  were 
treated by hot reflux extraction with 1.8 L ethanol-water 
(80:20, V/V) solution for 1.5h. Extract solution of ROR 
was concentrated to dryness using by the ethanol solvent 
in  a  rotary  evaporator  (Shanghai  SENCO  Science  & 
Technology  Co.,  Ltd.,  China)  at  60
oC.  Subsequently, 
sterilized  water  was  added,  and  then  the  liquid  was 
centrifuged  with  2500  rpm  for  15  min  to  obtain  the 
sample  solutions.  Then  the  collected  solution  was 
concentrated and filtered by 0.45μm filter until the crude 
ROR concentration reached to 5g/ml. Finally the pyrogen 
were removed by activated charcoal and pH monitored to 
7.0,  the  final  ROR  extracts  were  sterilized  by  0.22μm 
filter.  All  other  chemicals  were  of  analytical  grade  and 
purchased from commercial sources. 
 
Tumor cell lines and culture conditions 
The  K562  cell  line,  a  highly  undifferentiated  human 
erythroleukemic  cell  line  which  does  not  express  MHC 
class 1 molecules, was provided by Chinese Academy of 
Medical  Sciences,  Beijing,  were  maintained  in  RPMI 
1640  medium  containing  10%  of  FCS,  100 U/ml  of 
penicillin  and  100 U  /ml  of  streptomycin  at  2×10
6 
cells/ml. 
 
ROR solution Co-culture with CIK cells   
Briefly, 50mL heparinized peripheral blood was obtained 
from  an  eligible  patient.  The  peripheral  blood 
mononuclear  cells  (PBMCs)  were  isolated  by 
Ficoll-Hypaque  (ρ:  1.077±0.002)  density  centrifugation. 
The cells were divided individually into six groups with 2 
×10
6 cells/ml. Group 1 were incubated with routine CIK 
cells culture method. The PBMCs were then incubated in 
fresh  serum-  free  medium  (Takara,  Japan)  with 
IFN-γ(1000 U/mL; Shanghai Clonbiotech, China). After 
24 hours of incubation in a humidified atmosphere with 
5%  CO2  at  37
oC,  biochemically  purified  murine 
monoclonal T3 antibody (100 ng/mL, muromonab-CD3; 
Janssen Pharmaceutica, Titusville, NJ), IL-2 (1000U/ mL; 
Sihuan  Pharmaceutical  Co.,  Beijing,  China),  and  IL-1a 
(1000 U/mL; eBioscience, San Diego, CA) were added. 
IL-2  was  added  every  3–4  days  regardless  of  cell 
concentration. 
Group  2-6  were  treated  with  different  ROR  solutions 
concentration (1%, 3%, 5%, 7%, 9%) on day 0. The same 
regimes,  as  above,  were  followed  after  24h  incubation. 
Different concentration ROR solutions were co-cultured 
in  a  640-cm
2  bag  for  investigating  the  effect  of  ROR. 
Each of the individual culture bags was sampled on day 
11 for sterility testing, and then, on day 14, the cells were 
harvested  and  washed  twice  in  saline  water  with  1% 
human serum albumin. 
 
Proliferation assessment 
The cells proliferation of eight groups were assessed by 
using  MTT  [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide, Sigma] assay, which is based on the 
conversion of MTT to MTT-formazan by  mitochondrial Chen Chun
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enzymes.  Viable  cell  numbers  were  determined  by  the 
trypan blue exclusion method using a hemacytometer. 
 
Chromium release cytotoxicity assay 
The ability of CIK cells to lyse K562 (MHC devoid target 
cells) was examined using a standard chromium release 
cytotoxicity assay
16. Two million K562 cells were labeled 
with 50 μCi Na2
51CrO4 (Amersham International, UK) for 
1 h at 37 °C, 5% CO2. For effector/target (E/T) titration 
assays,  ROR  co-cultured  CIK  cell  and 
51Cr  K562  cells 
were  plated  at  10
4  cells/well  in  round-bottom  96-well 
plates with the following E/T ratios (1:1, 5:1, 10:1 and 
20:1) for 4h incubation. Supernatant was harvested after 4 
hours  incubation  at  37°C  and  5%  CO2.  Spontaneous 
release was determined by incubating target cells with an 
equal  volume  of  media  only  (no  effector  cells)  and 
maximum  release  was  determined  by  incubating  target 
cells  in  medium  containing  1%  aqueous  solution  of 
NP-40. Cells were co-incubated for four hours at 37°C, 
and then 100 μl of supernatant was transferred to another 
microplate.  Microplate  counting  of  supernatants  was 
measured by gamma counting with Packard Cobra 5010 
(Perkinelmer,  USA).  The  percent  specific  lysis  was 
calculated  as  follows:  [(E  -  M)/(T  -  M)]  ×100;  T= 
maximal  release,  M  =  spontaneous  release,  E  = 
experimental release. 
 
Statistical analysis 
Data  are  expressed  as  means±SD.  Duncan’s  multiple 
range tests was used to determine the difference among 
groups.  P-values  of  less  then  0.05  were  considered 
significant. 
 
Table 1: Cytotoxic activity of routine culture CIK and ROR-adding CIK groups against K562 cells 
 
Group  Effector-Target (E/T) ratio 
20:1  10:1  5:1  1:1 
routine culture CIK  83.43±0.98 a  65.25±2.37 a  42.73±2.45 a  10.19±0.93 a 
1% ROR-adding CIK  85.51±1.35 a  69.38±2.75 a  49.24±3.12 b  11.21±0.78 a 
3% ROR--adding CIK  84.22±0.72 a  66.33±1.31 a  48.37±1.78 b  10.45±1.21 a 
5% ROR--adding CIK  85.57±0.89 b  70.19±1.67 b  47.96±3.25 a  11.32±1.14 a 
7% ROR--adding CIK  84.74±1.03 a  69.26±1.97 a  45.71±1.75 a  10.78±0.91 a 
9% ROR--adding CIK  83.14±1.27 a  64.62±2.48 a  42.26±2.93 a  10.93±1.82 a 
All data were expressed with mean±SD. Different letters differed significantly in height (P <0.05) compared with CIK 
 
Figure 1: The proliferation multiples of CIK cells with different ROR-adding treatments. The bars with different lowercase letters differed 
significantly in height (P <0.05) based on ANOVA. Error bars: SD. Chen Chun
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RESULTS 
Proliferation assessment 
The CIK proliferation multiples of each group in day 14, 
based on the initial PBMCs populations 2×10
6 cells/ml, 
are  illustrated  in  Fig  1.  The  proliferation  multiples 
(610±20)  presented  5%  ROR-adding  group  was  the 
highest among all groups. The proliferation multiples of 
other five groups were assessed as no ROR-adding group 
(200±14),  1%  ROR-adding  group  (234±29),  3% 
ROR-adding  group  (421±27),  7%  ROR-adding  group 
(180±27), 9% ROR-adding group (120±24) respectively. 
5%  ROR-adding  group  is  2.8  folds  than  the  routine 
culture method of CIK cells. CIK proliferation rate of 5% 
ROR-adding  group  and  3%  ROR-adding  group  were 
significantly higher than those of other four groups (P < 
0.05) and there was significant difference between those 
two  groups  (P  <  0.05).  The  proliferation  rate  of  9% 
ROR-adding  group  was  the  lowest,  even  less  than  the 
control, no ROR-adding CIK cell group. 
 
Cytotoxicity of CIK cells against tumor cells 
An effector-target (E/T) cell ratio of CIK and ROR-CIK 
groups were investigated against the K562 cell line. As it 
showed in table 1, the cytotoxic activity of CIK cells from 
different  groups  was  growing  with  the  E/T  cell  ratio 
increasing. The 5% ROR-adding CIK cell group obtained 
the highest level  of cytotoxic activity (85.57±0.89)% at 
20:1  E/T  ratio,  (70.19±1.67)%  at  10:1  E/T  ratio, 
simultaneously.  Furthermore,  cytotoxic  activity  of  CIK 
cells from 3% and 5% ROR- adding CIK groups (both) 
had  significant  difference  in  comparison  control  (no 
ROR-  adding)  CIK  cell(P<0.05).  Additionally,  the 
cytotoxic activity of CIK  cells from 1% and 3% ROR- 
adding CIK groups were higher than control CIK group, 
however 5% was not at 5:1 E/T ratio. At 1:1 E/T ratio, 
there were no significant differences among these groups 
on the cytotoxic activity of CIK cells. 
 
DISCUSSION 
CIK cells are promising  for the immunotherapy  against 
residual tumor cells because of the in vitro proliferation. 
Therefore, the quality and quantity of CIK cell in vitro 
should play a crucial role for its potential immunotherapy. 
Although  ingredients  of  ROR  have  not  been  identified 
instantly  however  the  good  proliferation  and  high 
anti-tumor effect were demonstrated in the present study. 
Comparison with different concentration ROR-adding and 
routine  culture  method,  CIK  cells  groups  stimulated  by 
IFN-γ,  muromonab-CD3,  IL-2  etc.  showed  that  CIK 
populations of the former treatments changed earlier and 
much  more  continuous  than  that  of  the  later.  Previous 
studies  on  phytohemagglutinin  (PHA)  found  that 
appropriate  concentration  of  PHA  could  activate  the 
Ca
2+-dependent  pathways  to  secrete  IL-2  inducing  the 
CIK cells proliferation
6. This could also be an applausive 
reason  for  our  results.  Various  inducers  in  ROR 
co-culturing with cytokines, the proliferation function was 
activated  strongly  to  promote  the  CIK  populations. 
Consequently, not only the ingredient of ROR but also the 
optimum  dose  and  the  pre-stimulation  time  should  be 
worthy for further investigation. 
Obviously, stronger cytotoxic activity could provide much 
more confidence for clinical immunotherapy. In this study, 
5% ROR-adding CIK cells group was illustrated to have 
higher cytotoxic activity against K562 cell line based on 
the effector-target factor. However, the differences were 
not  always  significant.  At  5:1  E/T  ratio,  the  cytotoxic 
activity of CIK cell from 5% ROR-adding group has no 
difference  with  the  control  (no  ROR-adding  group), 
unlike that from 1% and 3% group. The possible reason 
could  be  inhibitors  in  ROR  solutions.  So  the  low 
concentration of ROR-adding should be considered mild 
before all ingredients were identified. 
Conclusively, the appropriate concentration ROR-adding 
could  improve  the  CIK  proliferation  multiples  and  its 
anti-tumor effect. It seems that the anti-tumor effects of 
TCMs  could  be  triggered  through  inactivating  the  T 
lymphocytes,  such  as  CIK  cells.  TCMs,  especially 
fuzheng  drugs  can  activate  immune  cell  activity  and 
phagocytosis  is  enhanced  while  improving  immune 
function, thereby it indirectly improve the quality of life 
of cancer patients and prolong the survival. 
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